13.46USD-7.36%Mkt Cap: 1.72B USDP/E: —Last update: 2026-05-26
Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses pro…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap1.72B USD
Enterprise Value1.34B USD
Revenue (TTM)30.30M USD
Gross Profit-205.39M USD
Net Income (TTM)-203.15M USD
Revenue/Share0.5210 USD
Last Price13.46 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees312
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-6.77
PEG—
EV/EBITDA-5.63
EV/Revenue44.26
P/S59.15
P/B-1.14
EPS (TTM)-2.07
EPS (Forward)-2.06
52W Range
11.0043% of range16.75
52W High16.75 USD
52W Low11.00 USD
Profitability
Gross Margin0.00%
Oper. Margin-887.49%
EBITDA Margin0.00%
Profit Margin-636.99%
ROE32.98%
ROA-61.53%
Growth
Revenue Growth-18.10%
Earnings Growth—
Cash Flow & Leverage
Operating CF-200.62M USD
CapEx (TTM)3.51M USD
FCF Margin—
FCF Yield—
Net Debt-451.07M USD
Net Debt/EBITDA1.89
Balance Sheet
Debt/Equity-0.11
Current Ratio9.17
Quick Ratio8.85
Book Value/Sh-12.2450 USD
Cash/Share4.030 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)25.40 USD
Target Range22.00 USD – 30.00 USD
# Analysts5
Ownership
Shares Out.128.19M
Float59.92M
Insiders23.14%
Institutions71.74%
Short Interest
Short Ratio9.4d
Short % Float4.30%
Short % Out.2.49%
Shares Short3.18M
Short (prev mo.)1.36M
Technical
SMA 5013.00 (+3.6%)
SMA 20012.86 (+4.6%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)497.19K
Avg Vol (10d)754.82K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—